NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Phenotyping Responses to Systemic Corticosteroids in the Management of Asthma Attacks

CompletedN/A

Sponsor: Université de Sherbrooke

Conditions: Asthma

Interventions: Visit 1: Clinical exam and questionnaires, Visit 1: Respiratory physiology, Visit 1: Inflammometry, Visit 2: Clinical exam and questionnaires, Visit 2: Respiratory physiology

Countries: Canada

This observational study compares the phenotypic variability (clinical and biological) in treatment response to systemic corticosteroids according to the blood eosinophil count and FeNO in physician-diagnosed ≥12-year-old asthmatics presenting with an asthma attack and healthy controls. Multimodal clinical and translational assessments will be performed on 50 physician-diagnosed, ≥12-year-old asthma patients presenting with an asthma attack and 12 healthy controls. These will include a blood eosinophil count, FeNO, and testing for airway infection (conventional sputum cultures and POC nasopharyngeal swabs). People with asthma will be assessed on day 0 and after a 7-day corticosteroid course, with in-home monitoring performed in between.

Eligibility overview

Sex: ALL

Age: 12 Years to —

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients ≥12 years old with physician-diagnosed asthma for \>6 months
* Experiencing an asthma attack with a patient and/or physician's decision to initiate a burst of systemic corticosteroids (but not yet started)
* Assessed within 24 hours on weekdays after a screening telephone call.
* For healthy volunteers: Non-atopic, non-smoking subjects with normal spirometry and no history of lung disease

Exclusion Criteria:

* Asthma treated with a monoclonal antibody or maintenance oral glucocorticosteroids
* Current smoking
* SARS-CoV-2-positive event
* Significant overlapping cardiopulmonary disease (including chronic obstructive pulmonary disease, defined as age \>40 years old AND persistent airflow limitation with FEV1/FVC\<0.7 AND \>10 pack-year smoking history (or alpha-1-antitrypsin deficiency))
* Confounding immunological state
* Pregnancy
* Contraindication to oral corticosteroids use

Locations (1)

Sherbrooke, Quebec, Canada